- Targets for 2015 clearly achieved
- Plans to increase the dividend by 15 percent to €1.15 per share
Essen, January 11, 2016— The Executive Board of Evonik Industries AG resolved today - based on the provisional figures for 2015 - that it aims for a dividend for the last fiscal year in the amount of €1.15 per share. That would be an increase of 15 percent from the previous year's dividend of €1.00 per share. Contingent upon the approval of the Supervisory Board, a corresponding dividend proposal would be made to the Annual Shareholders' Meeting on May 18, 2016.
Following an initial overview of past fiscal year 2015, the Executive Board has come to the conclusion that the targets set for 2015 were clearly achieved. The Executive Board anticipates an adjusted EBITDA of around €2.4 billion for 2015, with sales of around €13.5 billion. Klaus Engel, Chairman of the Executive Board: "It is already clear that we ended the past fiscal year successfully. We would like our shareholders to participate in that. Our intention of raising the dividend is also coupled with confidence that we can shape the new fiscal year successfully."
The corresponding increase in the payout continues Evonik Industries AG's attractive dividend policy, which aims for a payout ratio of around 40 percent of adjusted net income and dividend continuity. Moreover, the high operating cash flow in the past fiscal year allows a considerable increase in the dividend without impairing the Group's ambitious growth targets. Evonik has increased the dividend by an average of 9 percent per year over the past six years, positioning it among the most attractive dividend-paying shares.
Evonik will be publishing its results for fiscal year 2015 and the joint dividend proposal of the Executive Board and Supervisory Board on March 3, 2016.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.